Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial
Por:
Dimopoulos, M, Delimpasi, S, Manier, S, Michot, JM, Ocio, E, Rubinstein, S, Cook, J, Chamorro, MDM, Breazna, A, Dhadwal, A, Ghodke, Y, Masinde, S, Kroog, G, Sarkaria, S and Oriol, A
Publicada:
1 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Filiaciones:
Dimopoulos, M:
Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Athens, Greece
Delimpasi, S:
Evangelismos Gen Hosp, Dept Haematol & Bone Marrow Transplantat Unit, Athens, Greece
Manier, S:
Lille Univ Hosp, Hematol Dept, Lille, France
Michot, JM:
Gustave Roussy Canc Campus, Villejuif, France
Ocio, E:
Univ Cantabria Santander, Marques de Valdecilla Univ Hosp IDIVAL, Serv Hematol & Hemoterapia, Hosp Univ, Santander, Spain
Rubinstein, S:
Univ North Carolina, Dept Hematol Oncol, Chapel Hill, NC USA
Cook, J:
Mayo Clin, Rochester, NY USA
Chamorro, MDM:
Hosp Univ Quironsalud Madrid, Hematol Dept, Madrid, Spain
Univ Europea Madrid, Madrid, Spain
Breazna, A:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
Dhadwal, A:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
Ghodke, Y:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
Masinde, S:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
Kroog, G:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
Sarkaria, S:
Regeneron Pharmaceut Inc, Tarrytown, NY USA
:
Inst Catala Oncol, Dept Hematol, Badalona, Spain
Inst Josep Carreras Hosp Germans Trias i Pujol, Badalona, Spain
Bronze
|